In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Butoxyethanol “Safe As Used” Despite NTP Carcinogenicity Issues – CIR

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel unanimously agreed to reaffirm its final, "safe as used" recommendation for butoxyethanol at a meeting in Washington, D.C. Feb. 11-12

You may also be interested in...



CIR "Proactive" Approach To Seeking Controversial Ingredients Data Urged

The Cosmetic Ingredient Review Expert Panel should be "proactive" in conducting literature searches on controversial cosmetic ingredients up for re-review, CIR Director and Scientific Coordinator Alan Anderson urged during the panel's Sept. 10-11 meeting in Washington, D.C.

SAFE USE OF ISOBUTYLPARABEN, ISOPROYPLPARABEN CONFIRMED BY CIR

SAFE USE OF ISOBUTYLPARABEN, ISOPROYPLPARABEN CONFIRMED BY CIR in a final report issued at a Feb. 28-March 1 meeting of the Cosmetic Ingredient Review expert pane in Washington, D.C. At CIR's Nov. 22-23 meeting, the group reached a tentative final conclusion that the ingredients are safe as used ("The Rose Sheet" Nov. 29, p.8).

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel